Paving the way for anti-Abeta active immunotherapy
European Pharmaceutical Review
SEPTEMBER 22, 2023
She has extensive experience in the biopharmaceutical industry and previously served as Chief Scientific Officer for Novimmune from 2005.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
European Pharmaceutical Review
SEPTEMBER 22, 2023
She has extensive experience in the biopharmaceutical industry and previously served as Chief Scientific Officer for Novimmune from 2005.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content